Continuous vaccine manufacturing: challenges and technological solutions

Continuous manufacturing has been widely proposed as a transformative approach to vaccine production, offering higher productivity, reduced facility footprint, and improved supply resilience. While upstream intensification technologies such as perfusion and fixed‑bed bioreactors have matured, downstream purification and regulatory implementation remain major bottlenecks preventing widespread end‑to‑end continuous operation. This review synthesizes published research, industrial reviews, and vendor application knowledge to analyze technical bottlenecks across upstream and downstream vaccine manufacturing. Available continuous manufacturing technologies, including continuous cultivation strategies, single‑pass tangential flow filtration (SPTFF) and multi‑column chromatography, are discussed in the context of vaccine‑specific constraints. Finally, regulatory perspectives are examined, with emphasis on batch definition, validation, and lifecycle management in continuous vaccine manufacturing. The review highlights that successful implementation requires system‑level integration of process design, analytics, automation, and regulatory strategy.

Continuous manufacturing offers higher productivity, smaller facility footprints, and improved supply resilience for vaccine production – yet downstream purification and regulatory frameworks remain the primary barriers to widespread end-to-end implementation.

What you will learn

01

How perfusion and fixed-bed bioreactors overcome upstream capacity bottlenecks

02

How SPTFF and multi-column chromatography enable continuous downstream processing

03

How regulatory frameworks such as ICH Q13 define batch in continuous vaccine manufacturing

Batch vs continuous manufacturing

Traditional batch

Long production lead times (months)

Entire lot lost on batch failure

Large facility footprint & capital cost

Limited surge capacity for pandemics

Sequential unit operations with hold steps

Continuous manufacturing

Faster production with smaller bioreactors

Real-time QC and in-line release testing

>50% reduction in facility footprint

Scalable pandemic-response capacity

PAT-enabled closed-loop process control

Key technologies covered

1

Perfusion & fixed-bed bioreactors

2

Single-pass tangential flow filtration

3

Multi-column & membrane chromatography

4

PAT, digital twins & ICH Q13 compliance

Key findings

Upstream intensification is mature – perfusion and fixed-bed bioreactors deliver 2–4 log increases in viral titer, but shift the bottleneck to downstream purification

SPTFF reduces setup time 20-fold and facility footprint by 60% versus conventional TFF, with stable operation exceeding 20 hours without significant membrane fouling

Multi-column chromatography achieves >95% resin utilisation and up to 90% buffer reduction compared to single-column batch processes

Regulatory gaps remain the primary barrier – batch definition, process validation, and lifecycle management under ICH Q13 require system-level integration of QbD, PAT, and risk management

Key interests

Continuous Manufacturing

Vaccine Production

Perfusion Bioreactors

Downstream Processing

ICH Q13

Process Analytical Technology